Abbott Announces Acceptance in China for Next-Era XIENCE V Medication Eluting Stent Abbott announced today that the Chinese Condition Food and Drug Administration has approved its XIENCE V Everolimus Eluting Coronary Stent Program for the treating coronary artery disease – the leading cause of death in China. XIENCE V is the only medication eluting stent to possess demonstrated superiority over the TAXUS Paclitaxel-Eluting Coronary Stent System in the principal endpoints of two randomized, pivotal scientific trials. The ongoing firm plans a fourth-quarter release for XIENCE V in China, which may be the second-largest medication eluting stent marketplace in the Asia-Pacific area after Japan pharmacy online .
Placebo. .. AVEO presents tivozanib Phase 2 study results at ESMO Congress AVEO Pharmaceuticals, Inc. , a biopharmaceutical business focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported outcomes from its Phase 2 research evaluating tivozanib for the treating advanced renal cell carcinoma were shown at the 35th European Society for Medical Oncology Congress in Milan, Italy. ESMO may be the leading European oncology professional business, focused on advancing the specialty of medical oncology and promoting a multidisciplinary method of cancer treatment and care.D., Sc.M., chief medical officer at AVEO.